A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target p53 mutations and other p53-related cancers.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 7.4M | - | - | - | - | - |
| Net Income | -83M | -59M | -69M | -73M | -58M | -34M |
| EPS | $-1.59 | $-1.14 | $-1.44 | $-1.61 | $-1.28 | $-2.40 |
| Free Cash Flow | -73M | -52M | -57M | -72M | -48M | -33M |
| ROIC | -54.4% | -33.3% | -30.6% | -29.8% | -18.7% | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.09 | 0.12 | 0.10 | 0.07 | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -92M | -85M | -80M | -77M | -58M | -35M |
| Operating Margin | -1246.4% | - | - | - | - | - |
| ROE | -68.4% | -29.2% | -30.6% | -29.8% | -18.7% | - |
| Shares Outstanding | 53M | 51M | 48M | 46M | 45M | 14M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 7.4M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -27M | -35M | -58M | -77M | -80M | -85M | -92M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1246.4% |
| Net Income | -25M | -34M | -58M | -73M | -69M | -59M | -83M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1118.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -20.4% | N/A | -18.7% | -29.8% | -30.6% | -33.3% | -54.4% |
| ROE | N/A | N/A | -18.7% | -29.8% | -30.6% | -29.2% | -68.4% |
| ROA | -24.6% | -9.4% | -17.4% | -27.1% | -27.3% | -26.5% | -61.8% |
| Cash Flow | |||||||
| Op. Cash Flow | -22M | -33M | -47M | -64M | -56M | -51M | -73M |
| Free Cash Flow | -22M | -33M | -48M | -72M | -57M | -52M | -73M |
| Owner Earnings | -23M | -35M | -52M | -74M | -69M | -61M | -83M |
| CapEx | 109K | 148K | 1.3M | 8.0M | 962K | 655K | 70K |
| Maint. CapEx | 388K | 318K | 307K | 315K | 1.3M | 1.1M | 1.1M |
| Growth CapEx | 0 | 0 | 1.0M | 7.7M | 0 | 0 | 0 |
| D&A | 388K | 318K | 307K | 315K | 1.3M | 1.1M | 1.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 908K | 1.9M | 5.3M | 10M | 12M | 8.9M | 8.9M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -129M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 129M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -2.46 | N/A | 0.07 | 0.10 | 0.12 | 0.09 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -70M | N/A | 309M | 246M | 226M | 176M | 121M |
| Total Assets | 103M | 366M | 332M | 270M | 252M | 191M | 134M |
| Total Liabilities | 174M | N/A | 23M | 24M | 26M | 15M | 13M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -75M | -110M | -168M | -241M | -310M | -369M | -369M |
| Working Capital | 98M | 358M | 289M | 236M | 193M | 161M | 161M |
| Current Assets | 102M | 365M | 301M | 247M | 207M | 176M | 176M |
| Current Liabilities | 4.5M | 6.4M | 12M | 11M | 14M | 14M | 14M |
| Per Share Data | |||||||
| EPS | -8.35 | -2.40 | -1.28 | -1.61 | -1.44 | -1.14 | -1.59 |
| Owner EPS | -0.52 | -2.44 | -1.16 | -1.63 | -1.45 | -1.19 | -1.56 |
| Book Value | -1.57 | N/A | 6.83 | 5.40 | 4.71 | 3.42 | 2.27 |
| Cash Flow/Share | -0.49 | -2.28 | -1.03 | -1.40 | -1.16 | -1.00 | -1.53 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 44.8M | 14.3M | 45.2M | 45.5M | 47.9M | 51.5M | 53.2M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -0.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 3.4 | 1.5 | 0.7 | 0.4 | 0.6 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 9.7 |
| FCF Yield | N/A | -4.4% | -4.6% | -19.1% | -37.3% | -67.2% | -101.8% |
| Market Cap | N/A | 748M | 1.0B | 376M | 152M | 77M | 72M |
| Avg. Price | N/A | 38.26 | 32.62 | 14.50 | 5.49 | 1.70 | 1.35 |
| Year-End Price | N/A | 52.14 | 23.23 | 8.25 | 3.17 | 1.50 | 1.35 |
PMV Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
PMV Pharmaceuticals, Inc. (PMVP) has a 5-year average return on invested capital (ROIC) of -28.1%. This is below average and may indicate limited pricing power.
PMV Pharmaceuticals, Inc. (PMVP) has a market capitalization of $72M. It is classified as a small-cap stock.
PMV Pharmaceuticals, Inc. (PMVP) does not currently pay a regular dividend.
PMV Pharmaceuticals, Inc. (PMVP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PMV Pharmaceuticals, Inc. (PMVP) generated $-52 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PMV Pharmaceuticals, Inc. (PMVP) has a debt-to-equity ratio of 0.09. This indicates a conservatively financed balance sheet.
PMV Pharmaceuticals, Inc. (PMVP) reported earnings per share (EPS) of $-1.14 in its most recent fiscal year.
PMV Pharmaceuticals, Inc. (PMVP) has a return on equity (ROE) of -29.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for PMV Pharmaceuticals, Inc. (PMVP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PMV Pharmaceuticals, Inc. (PMVP) has a book value per share of $3.42, based on its most recent annual SEC filing.